IL2 and cancer: Several pilot studies have described a partial success of γδ T cell-based immunotherapy in different types of cancer after the application of aminobisphosphonates (n-BP) or phosphorylated antigens (PAg) plus IL-2 in vivo or after repetitive transfer of in vitro expanded Vδ2-expressing γδTc (7–10).